Xiaohu Zheng

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Risk Assessment

Top Venues

Cancer biology & medicine

Nature immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Shuangcheng Li, Tianci Wang, Xinghui Xiao, Xiaodong Zheng, Haoyu Sun, Rui Sun, Hongdi Ma, Zhigang Tian, Xiaohu Zheng
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine 21 (4) (2024)
Shuangcheng Li, Tianci Wang, Xinghui Xiao, Xiaodong Zheng, Haoyu Sun, Rui Sun, Hongdi Ma, Zhigang Tian, Xiaohu Zheng
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine 21 (4) (2024)
Shuangcheng Li, Tianci Wang, Xinghui Xiao, Xiaodong Zheng, Haoyu Sun, Rui Sun, Hongdi Ma, Zhigang Tian, Xiaohu Zheng
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine 21 (4) (2024)
Shuangcheng Li, Tianci Wang, Xinghui Xiao, Xiaodong Zheng, Haoyu Sun, Rui Sun, Hongdi Ma, Zhigang Tian, Xiaohu Zheng
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine 21 (4) (2024)
Shuangcheng Li, Tianci Wang, Xinghui Xiao, Xiaodong Zheng, Haoyu Sun, Rui Sun, Hongdi Ma, Zhigang Tian, Xiaohu Zheng
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine (2024)
Shuangcheng Li, Tianci Wang, Xinghui Xiao, Xiaodong Zheng, Haoyu Sun, Rui Sun, Hongdi Ma, Zhigang Tian, Xiaohu Zheng
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine 21 (4) (2024)
Xiaohu Zheng, Zhuanghao Hou, Yeben Qian, Yongwei Zhang, Quanwei Cui, Xuben Wang, Yiqing Shen, Zhenbang Liu, Yonggang Zhou, Binqing Fu, Rui Sun, Zhigang Tian, Guangming Huang, Haiming Wei
Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nature immunology (2023)